Identification of a glioma antigen, GARC-1, using cytotoxic T lymphocytes induced by HSV cancer vaccine.
about
Downregulation of KIF23 suppresses glioma proliferationImmunocompetent murine models for the study of glioblastoma immunotherapyEffective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10.Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent mannersCombination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells.OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy.Effective Treatment of Established GL261 Murine Gliomas through Picornavirus Vaccination-Enhanced Tumor Antigen-Specific CD8+ T Cell Responses.CD40/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models.Profound impairment of adaptive immune responses by alkylating chemotherapySystemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccinesExperimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model.Local convection-enhanced delivery of an anti-CD40 agonistic monoclonal antibody induces antitumor effects in mouse glioma models.Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach.Gene therapy and targeted toxins for glioma
P2860
Q28247603-63CE6D8B-7B27-406C-9DD6-F34E18B8C38DQ33574853-C54145A9-82E8-4B52-998F-4B70863CF64CQ33744525-D3F56CAB-842A-492E-8753-D1D434FD1CB0Q33945653-FACACFD2-5D4F-45BC-8273-DE9C72F99676Q34457611-7DCB6C6F-AF28-4D28-984D-BBFDCC22EB9EQ35118177-8F8440DD-F0D3-4DF0-85A6-592CF093E785Q35561280-7ECCDBCF-B855-4179-A378-0DFCBD57209FQ36288270-F0502B1E-A063-4DAB-9763-6B36027C27F2Q36922577-C902767D-504C-4C39-8B69-6BC2D99C1D7EQ37438563-84791D1F-2902-4A18-BD2F-6557212C3637Q37814208-2FCB4233-0FE0-4999-81F9-428B2E97CD55Q42431590-95EDF1FB-A5DA-40D7-93B7-636403997903Q46217247-A3F8ED54-2C70-42EA-A03F-1B12F43A0451Q57006162-68536266-39B1-4470-9654-710C92E7370F
P2860
Identification of a glioma antigen, GARC-1, using cytotoxic T lymphocytes induced by HSV cancer vaccine.
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Identification of a glioma ant ...... induced by HSV cancer vaccine.
@ast
Identification of a glioma ant ...... induced by HSV cancer vaccine.
@en
type
label
Identification of a glioma ant ...... induced by HSV cancer vaccine.
@ast
Identification of a glioma ant ...... induced by HSV cancer vaccine.
@en
prefLabel
Identification of a glioma ant ...... induced by HSV cancer vaccine.
@ast
Identification of a glioma ant ...... induced by HSV cancer vaccine.
@en
P2093
P356
P1476
Identification of a glioma ant ...... induced by HSV cancer vaccine.
@en
P2093
Hidefumi Kojima
Masahiro Toda
Takeshi Kawase
Tetsuji Kobata
Yukihiko Iizuka
Yutaka Kawakami
P2860
P304
P356
10.1002/IJC.21432
P577
2006-02-01T00:00:00Z